

A phase III trial of empiric chemotherapy with cisplatin
treatment tailored by molecular gene expression analysis
in an unknown primary (CUP) site (GEFCAPI 04)

Annals of Oncology

30, v851

DOI: [10.1093/annonc/mdz394](https://doi.org/10.1093/annonc/mdz394)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Emerging Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. <i>Medicina (Lithuania)</i> , 2019, 55, 698.	0.8	54
2	Systemic treatment of biliary tract cancer: now we have the evidence. <i>Annals of Oncology</i> , 2019, 30, 1851-1852.	0.6	0
3	Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2019, 30, 1884-1901.	0.6	394
4	The value of prostate-specific antigen monitoring during salvage radiotherapy: a retrospective study and systematic review with meta-analysis. <i>Journal of Radiation Oncology</i> , 2019, 8, 413-423.	0.7	2
5	Immune checkpoints inhibitors rechallenge in non-small-cell lung cancer: different scenarios with different solutions?. <i>Lung Cancer Management</i> , 2019, 8, LMT18.	1.5	17
6	Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers. <i>Cancers</i> , 2019, 11, 1926.	1.7	27
7	Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer. <i>Future Oncology</i> , 2020, 16, 4439-4453.	1.1	29
8	Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical) Tj ETQq1 1 0.784314 rgBT /Overload	2.0	39
9	Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma. <i>Current Opinion in Oncology</i> , 2020, 32, 79-84.	1.1	25
10	Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity. <i>Future Oncology</i> , 2020, 16, 129-145.	1.1	5
11	The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma. <i>Cancer Treatment Reviews</i> , 2020, 82, 101925.	3.4	73
12	Frontline immunotherapy for NSCLC – the tale of the tail. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 73-74.	12.5	35
13	ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer. <i>Future Oncology</i> , 2020, 16, 4359-4368.	1.1	61
14	Therapeutic breakthroughs for metastatic thyroid cancer. <i>Nature Reviews Endocrinology</i> , 2020, 16, 77-78.	4.3	31
15	Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations. <i>Drugs</i> , 2020, 80, 131-146.	4.9	10
16	The tip of the iceberg: predicting PARP inhibitor efficacy in prostate cancer. <i>Lancet Oncology</i> , The, 2020, 21, 17-19.	5.1	8
17	Personalized treatment in metastatic triple-negative breast cancer: The outlook in 2020. <i>Breast Journal</i> , 2020, 26, 69-80.	0.4	31
18	Immune checkpoint blockade and biomarkers of clinical response in non-small cell lung cancer. <i>Scandinavian Journal of Immunology</i> , 2020, 92, e12980.	1.3	14

#	ARTICLE	IF	CITATIONS
19	Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic. <i>Oncologist</i> , 2020, 25, e1562-e1573.	1.9	6
21	Transcriptomics and solid tumors: The next frontier in precision cancer medicine. <i>Seminars in Cancer Biology</i> , 2022, 84, 50-59.	4.3	36
23	Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System. <i>Hepatology</i> , 2021, 73, 2311-2325.	3.6	40
24	How current assay approval policies are leading to unintended imprecision medicine. <i>Lancet Oncology</i> , The, 2020, 21, 1399-1401.	5.1	34
25	Designing novel immunocombinations in metastatic renal cell carcinoma. <i>Immunotherapy</i> , 2020, 12, 1257-1268.	1.0	6
26	5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). <i>Annals of Oncology</i> , 2020, 31, 1623-1649.	0.6	761
27	Endocrine therapy in the management of low-grade serous ovarian/peritoneal carcinoma: Mounting evidence for the relative efficacy of tamoxifen and aromatase inhibitors. <i>Gynecologic Oncology</i> , 2020, 159, 601-603.	0.6	3
28	Understanding PD-L1 Testing in Breast Cancer: A Practical Approach. <i>Breast Care</i> , 2020, 15, 481-490.	0.8	34
29	Poly(ADP-Ribose) Polymerase Inhibitors in Prostate Cancer: Molecular Mechanisms, and Preclinical and Clinical Data. <i>Targeted Oncology</i> , 2020, 15, 709-722.	1.7	17
30	Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC). <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1355-1364.	1.9	39
31	Immunotherapy for Hepatocellular Carcinoma: Is Latin America Ready for Primetime?. <i>Clinical Liver Disease</i> , 2020, 16, 96-100.	1.0	0
32	Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. <i>Annals of Oncology</i> , 2020, 31, 1491-1505.	0.6	658
33	nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, 181-190.e2.	1.1	23
34	Should triple-positive breast cancer be recognized as a distinct subtype?. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 1011-1014.	1.1	15
35	The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance. <i>Gynecologic Oncology</i> , 2020, 158, 653-658.	0.6	29
36	A drug safety evaluation of atezolizumab in locally advanced or metastatic urothelial carcinoma. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 955-960.	1.0	3
37	Adjuvant chemotherapy in colon cancer: state of the art and future perspectives. <i>Current Opinion in Oncology</i> , 2020, 32, 370-376.	1.1	9
38	Survival analysis of patients with prostate cancer and unfavorable risk factors treated with radical prostatectomy and salvage radiotherapy after biochemical recurrence and persistence. <i>Actas Urológicas Españolas (English Edition)</i> , 2020, 44, 701-707.	0.2	2

#	ARTICLE	IF	CITATIONS
39	Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis. <i>Journal of Translational Medicine</i> , 2020, 18, 446.	1.8	1
40	A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?. <i>European Urology Oncology</i> , 2021, 4, 745-754.	2.6	17
41	Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC). <i>BMC Cancer</i> , 2020, 20, 1185.	1.1	75
42	The role of molecular profiling in the diagnosis and management of metastatic undifferentiated cancer of unknown primary ^o . <i>Seminars in Diagnostic Pathology</i> , 2021, 38, 193-198.	1.0	9
43	Update Breast Cancer 2020 Part 4 – Advanced Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 1115-1122.	0.8	11
44	Trastuzumab emtansine: a game changer in HER2-positive early breast cancer. <i>Future Oncology</i> , 2020, 16, 2595-2609.	1.1	3
45	Immunotherapy-based combination strategies for advanced urothelial cancer: A long quest. <i>Cancer</i> , 2020, 126, 4446-4450.	2.0	7
46	Immunotherapy in cervix cancer. <i>Cancer Treatment Reviews</i> , 2020, 90, 102088.	3.4	28
47	IMpower 131: The Exception to the Rule. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1258-1260.	0.5	1
48	Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2020, 21, 69.	1.3	20
49	Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver. <i>Lung Cancer Management</i> , 2020, 9, LMT36.	1.5	19
50	Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2 ⁺ metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 161-172.	1.1	3
51	The diagnostic challenges of patients with carcinoma of unknown primary. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 775-783.	1.1	12
53	New Verse for a Familiar Song: Small Molecule Inhibitors for MET exon 14 Skipping Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2020, 25, 822-825.	1.9	9
54	Liquid Biopsy as a Tool Exploring in Real-Time Both Genomic Perturbation and Resistance to EGFR Antagonists in Colorectal Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 581130.	1.3	7
55	Mise en place: toward neoadjuvant chemoimmunotherapy for early triple-negative breast cancer. <i>Annals of Oncology</i> , 2020, 31, 556-557.	0.6	0
56	Novel therapies are changing treatment paradigms in metastatic prostate cancer. <i>Journal of Hematology and Oncology</i> , 2020, 13, 144.	6.9	80
57	ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. <i>Annals of Oncology</i> , 2020, 31, 1449-1461.	0.6	69

#	ARTICLE	IF	CITATIONS
58	Resetting the Bar of Castration Resistance – Understanding Androgen Dynamics in Therapy Resistance and Treatment Choice in Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 199-207.	0.9	7
59	Adjuvant therapy for high-risk renal cell carcinoma after nephrectomy how many trials are positive? Only one or more than one. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 12-17.	0.7	1
60	Sequencing Systemic Therapy Pathways for Advanced Hepatocellular Carcinoma: A Cost Effectiveness Analysis. <i>Liver Cancer</i> , 2020, 9, 549-562.	4.2	14
61	Defining a Distinct Immunotherapy Eligible Subset of Patients with Cancer of Unknown Primary Using Gene Expression Profiling with the 92-Gene Assay. <i>Oncologist</i> , 2020, 25, e1807-e1811.	1.9	7
62	Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer – Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. <i>Breast</i> , 2020, 54, 88-95.	0.9	34
64	Predictive value of Prostate Specific Antigen variations in the last week of salvage radiotherapy for biochemical recurrence of prostate cancer after surgery: A practical approach. <i>Cancer Reports</i> , 2020, 3, e1285.	0.6	4
65	Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2020, 21, 1489-1499.	5.1	94
66	Gastric cancer. <i>Lancet</i> , The, 2020, 396, 635-648.	6.3	2,084
67	Safety and Effectiveness of Yttrium-90 Radioembolization around the Time of Immune Checkpoint Inhibitors for Unresectable Hepatic Metastases. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 1233-1241.	0.2	11
69	Molecular Profiling in Daily Clinical Practice: Practicalities in Advanced Cholangiocarcinoma and Other Biliary Tract Cancers. <i>Journal of Clinical Medicine</i> , 2020, 9, 2854.	1.0	61
70	Shifting paradigms in the systemic management of hepatocellular carcinoma. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 883-885.	3.7	1
72	When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials. <i>European Urology Oncology</i> , 2020, 3, 594-611.	2.6	63
74	Response to re-challenge of a MEK inhibitor in a patient with recurrent low-grade serous carcinoma of the peritoneum. <i>Gynecologic Oncology Reports</i> , 2020, 34, 100670.	0.3	1
75	Fibroblast Growth Factor Receptor 3 Mutation as a Prognostic Indicator in Patients with Urothelial Carcinoma: A Systematic Review and Meta-analysis. <i>European Urology Open Science</i> , 2020, 21, 61-68.	0.2	2
76	Are Pathogenic Germline Variants in Metastatic Melanoma Associated with Resistance to Combined Immunotherapy?. <i>Cancers</i> , 2020, 12, 1101.	1.7	9
77	Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden. <i>Oncologist</i> , 2020, 25, 803-809.	1.9	26
78	Dual Fulvestrant-Trametinib Therapy in Recurrent Low-Grade Serous Ovarian Cancer. <i>Oncologist</i> , 2020, 25, e1124-e1126.	1.9	4
79	PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 549-560.	2.0	36

#	ARTICLE	IF	CITATIONS
80	Role of Systemic Treatment for Advanced/Metastatic Gastric Carcinoma in the Third-Line Setting: A Bayesian Network Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 513.	1.3	3
81	Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study. <i>Oncologist</i> , 2020, 25, e1158-e1169.	1.9	11
82	Treatment of High Risk Resected Melanoma in Australia: Current Landscape and Practises. <i>Australasian Journal of Dermatology</i> , 2020, 61, 203-209.	0.4	4
83	Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic. <i>European Urology</i> , 2020, 78, 29-42.	0.9	110
84	Atezolizumab in the treatment of metastatic triple-negative breast cancer. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 981-989.	1.4	20
85	Resolution of a hepatoduodenal fistula after nivolumab treatment in a patient with hepatocellular carcinoma: challenges in immunotherapy. <i>Acta Clinica Belgica</i> , 2022, 77, 108-112.	0.5	4
86	The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1409-1424.	0.5	182
87	Immunotherapy in non-small-cell lung cancer: from targeted molecules to resistance patterns. <i>Pharmacogenomics</i> , 2020, 21, 705-720.	0.6	9
88	Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review. <i>BMC Cancer</i> , 2020, 20, 507.	1.1	48
90	Upcoming first-line chemotherapy for HER2-negative gastric cancer in Japan: which patients benefit from immunotherapy?. <i>Future Oncology</i> , 2020, 16, 1797-1799.	1.1	3
91	Clinical Development of PD-1/PD-L1 Inhibitors in Breast Cancer: Still a Long Way to Go. <i>Current Treatment Options in Oncology</i> , 2020, 21, 59.	1.3	12
92	Reaching out beyond first-line treatments in advanced biliary tract cancers. <i>Annals of Oncology</i> , 2020, 31, 1099-1102.	0.6	1
93	Molecular targeted therapies: Ready for "prime time" in biliary tract cancer. <i>Journal of Hepatology</i> , 2020, 73, 170-185.	1.8	226
94	Immune-based therapies for hepatocellular carcinoma. <i>Oncogene</i> , 2020, 39, 3620-3637.	2.6	154
95	Conquering lung cancer: current status and prospects for the future. <i>Pulmonology</i> , 2020, 26, 283-290.	1.0	51
96	Gray Areas in the Gray Matter: IDH1/2 Mutations in Glioma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 96-103.	1.8	6
97	Management of early-stage gastro-esophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 305-324.	1.1	0
98	ESMO 2019: breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 147-149.	0.3	1

#	ARTICLE	IF	CITATIONS
99	Immunotherapy as a Downstaging Therapy for Liver Transplantation. <i>Hepatology</i> , 2020, 72, 1488-1490.	3.6	59
100	Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. <i>Journal of Thoracic Oncology</i> , 2020, 15, 914-947.	0.5	119
101	The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immunotherapy biomarkers in breast cancer clinical trials and daily practice. <i>Journal of Pathology</i> , 2020, 250, 667-684.	2.1	142
102	A meta-analysis comparing responses of Asian versus non-Asian cancer patients to PD-1 and PD-L1 inhibitor-based therapy. <i>Oncolmmunology</i> , 2020, 9, 1781333.	2.1	34
103	Bevacizumab for Newly Diagnosed Ovarian Cancers: Best Candidates Among High-Risk Disease Patients (ICON-7). <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa026.	1.4	21
104	New Treatment Options for Advanced Biliary Tract Cancer. <i>Current Treatment Options in Oncology</i> , 2020, 21, 63.	1.3	27
105	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 557-588.	8.2	1,155
106	A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma. <i>Oncologist</i> , 2020, 25, e1457-e1463.	1.9	7
107	The immunotherapy revolution in genitourinary malignancies. <i>Immunotherapy</i> , 2020, 12, 819-831.	1.0	10
108	Homologous repair deficiencies and current insights in clinical evaluation of PARP inhibitors in prostate cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 371-374.	0.3	1
109	Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors. <i>Cancer Treatment Reviews</i> , 2020, 88, 102064.	3.4	41
111	The evolving management of metastatic triple negative breast cancer. <i>Seminars in Oncology</i> , 2020, 47, 229-237.	0.8	28
112	Dashing Decades of Defeat: Long Anticipated Advances in the First-line Treatment of Extensive-Stage Small Cell Lung Cancer. <i>Current Oncology Reports</i> , 2020, 22, 20.	1.8	11
113	Is it time to redefine cisplatin ineligibility in metastatic urothelial cancer?. <i>European Journal of Cancer</i> , 2020, 127, 158-159.	1.3	1
114	The emerging development of tumor mutational burden in patients with NSCLC. <i>Future Oncology</i> , 2020, 16, 469-481.	1.1	2
116	PD-L1/PD-1 axis as a potent therapeutic target in breast cancer. <i>Life Sciences</i> , 2020, 247, 117437.	2.0	33
117	Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16). <i>Annals of Oncology</i> , 2020, 31, 495-500.	0.6	25
118	Exploring the biological hallmarks of cancer of unknown primary: where do we stand today?. <i>British Journal of Cancer</i> , 2020, 122, 1124-1132.	2.9	41

#	ARTICLE	IF	CITATIONS
119	Germline and somatic mutations in prostate cancer: focus on defective DNA repair, PARP inhibitors and immunotherapy. <i>Future Oncology</i> , 2020, 16, 75-80.	1.1	11
120	The importance of exosomal PDL1 in tumour immune evasion. <i>Nature Reviews Immunology</i> , 2020, 20, 209-215.	10.6	360
121	Metastatic Cancer of Unknown Primary or Primary Metastatic Cancer?. <i>Frontiers in Oncology</i> , 2019, 9, 1546.	1.3	35
122	New rising entities in cancer of unknown primary: Is there a real therapeutic benefit?. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 147, 102882.	2.0	42
123	Milestones in the pathogenesis and management of primary liver cancer. <i>Journal of Hepatology</i> , 2020, 72, 209-214.	1.8	39
124	Multiplex immunohistochemistry/immunofluorescence (mlHC/IF) for PD-L1 testing in triple-negative breast cancer: a translational assay compared with conventional IHC. <i>Journal of Clinical Pathology</i> , 2020, 73, 557-562.	1.0	53
125	RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies. <i>Journal of Thoracic Oncology</i> , 2020, 15, 541-549.	0.5	189
126	Beyond the concept of cold and hot tumors for the development of novel predictive biomarkers and the rational design of immunotherapy combination. <i>International Journal of Cancer</i> , 2020, 147, 1509-1518.	2.3	44
127	The role of site-specific therapy for cancers of unknown of primary: A meta-analysis. <i>European Journal of Cancer</i> , 2020, 127, 118-122.	1.3	24
128	Top 10 Challenges in Cancer Immunotherapy. <i>Immunity</i> , 2020, 52, 17-35.	6.6	1,177
129	Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary. <i>International Journal of Cancer</i> , 2020, 146, 3053-3064.	2.3	14
130	Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). <i>International Journal of Cancer</i> , 2020, 147, 2493-2502.	2.3	22
131	Progress in refining the clinical management of cancer of unknown primary in the molecular era. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 541-554.	12.5	62
134	Radiotherapy after prostatectomy in high-risk prostate cancer. <i>Clinical and Translational Oncology</i> , 2020, 22, 2139-2140.	1.2	1
135	ESMO 2019 personal non-small lung cancer highlights. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 150-153.	0.3	1
136	Genomic-guided precision therapy for soft tissue sarcoma. <i>ESMO Open</i> , 2020, 5, e000626.	2.0	7
137	Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1351-1360.	0.5	379
138	Effect of Baseline Characteristics on Cabazitaxel Treatment Duration in Patients with Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the Compassionate Use/Expanded Access Programs and CAPRISTANA Registry. <i>Cancers</i> , 2020, 12, 995.	1.7	2

#	ARTICLE	IF	CITATIONS
139	Frontiers in combining immune checkpoint inhibitors for advanced urothelial cancer management. <i>Current Opinion in Urology</i> , 2020, 30, 457-466.	0.9	2
140	Recommendations to improve the clinical adoption of NGS-based cancer diagnostics in Singapore. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 222-231.	0.7	8
141	<p>Combination Strategies of Checkpoint Immunotherapy in Metastatic Breast Cancer</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 2657-2666.	1.0	9
142	Clinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future Trials. <i>Oncologist</i> , 2020, 25, 780-786.	1.9	14
143	Molecular Targets in Cholangiocarcinoma. <i>Hepatology</i> , 2021, 73, 62-74.	3.6	26
144	Treatment of Advanced Melanoma in 2020 and Beyond. <i>Journal of Investigative Dermatology</i> , 2021, 141, 23-31.	0.3	193
145	Clinical recommendations in the management of advanced prostate cancer: International Gastrointestinal, Liver and Uro-oncology (IGILUC 2019) experts. <i>World Journal of Urology</i> , 2021, 39, 1421-1429.	1.2	4
146	Biomarkers for Hepatobiliary Cancers. <i>Hepatology</i> , 2021, 73, 115-127.	3.6	104
147	Neoadjuvant selpercatinib for advanced medullary thyroid cancer. <i>Head and Neck</i> , 2021, 43, E7-E12.	0.9	42
148	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancerâ€™2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. <i>European Urology</i> , 2021, 79, 243-262.	0.9	1,545
149	Outcomes in older patients with biliary tract cancer. <i>European Journal of Surgical Oncology</i> , 2021, 47, 569-575.	0.5	5
150	Emergence of Resistant Clones in Medullary Thyroid Cancer May Not Be Rescued by Subsequent Salvage Highly Selective Rearranged During Transfection-Inhibitor Therapy. <i>Thyroid</i> , 2021, 31, 332-333.	2.4	8
151	PIVOT-10: Phase II study of bempagaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer. <i>Future Oncology</i> , 2021, 17, 137-149.	1.1	5
152	Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 289-298.	0.5	35
153	Systemic treatment of HCC in special populations. <i>Journal of Hepatology</i> , 2021, 74, 931-943.	1.8	72
154	Programmed cell death 1 ligand 1 (PD-L1) expression is associated with poor prognosis of malignant pleural mesothelioma patients with good performance status. <i>Pathology</i> , 2021, 53, 462-469.	0.3	11
155	Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103167.	2.0	30
156	Durvalumab, with or without tremelimumab, plus platinumâ€™etoposide versus platinumâ€™etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 51-65.	5.1	356

#	ARTICLE	IF	CITATIONS
157	Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design. <i>Oncologist</i> , 2021, 26, e394-e402.	1.9	39
158	Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory FoRECATT study. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1583-1592.	2.0	12
159	Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUP. <i>British Journal of Cancer</i> , 2021, 124, 721-727.	2.9	5
160	Milestones in the treatment of hepatocellular carcinoma: A systematic review.. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103179.	2.0	14
161	Alpelisib in the treatment of metastatic HR+ breast cancer with PIK3CA mutations. <i>Future Oncology</i> , 2021, 17, 13-36.	1.1	9
162	Salvage systemic therapy for metastatic urothelial carcinoma: an unmet clinical need. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 299-313.	1.1	6
163	The need for new algorithms of treatment sequencing in clear-cell metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 401-412.	1.1	8
164	Current status of PD-1/PD-L1 blockade immunotherapy in breast cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 321-332.	0.6	22
165	Systemic therapy of advanced hepatocellular carcinoma. <i>Future Oncology</i> , 2021, 17, 1237-1251.	1.1	31
166	Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer. <i>British Journal of Cancer</i> , 2021, 124, 552-563.	2.9	63
167	Optimizing therapy sequence to prevent patient attrition in EGFR mutation-positive advanced or metastatic NSCLC. <i>Future Oncology</i> , 2021, 17, 471-486.	1.1	11
168	Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 56-62.	12.5	99
169	Novel agents to target treatment resistance in ovarian cancer. , 2021, , 129-149.		0
170	Risk factors and predictors for tumor site origin in metastatic adenocarcinoma of unknown primary site. <i>Cancer Medicine</i> , 2021, 10, 974-988.	1.3	6
171	Immunotherapy in Triple-Negative Breast Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 59-66.	1.0	36
172	Vemurafenib and Cobimetinib. , 2021, , 149-165.		0
173	Cancer of Unknown Primary: Challenges and Progress in Clinical Management. <i>Cancers</i> , 2021, 13, 451.	1.7	24
176	Epithelial ovarian cancer: Genomic landscape and evolving precision treatment. , 2021, , 1-23.		0

#	ARTICLE	IF	CITATIONS
177	Refining Immuno-Oncology Approaches in Metastatic Prostate Cancer: Transcending Current Limitations. <i>Current Treatment Options in Oncology</i> , 2021, 22, 13.	1.3	12
178	Neoadjuvant and Adjuvant Therapies of Melanoma. , 2021, , 401-415.		0
179	History and emerging trends in chemotherapy for gastric cancer. <i>Annals of Gastroenterological Surgery</i> , 2021, 5, 446-456.	1.2	25
180	First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. <i>Cancers</i> , 2021, 13, 931.	1.7	26
183	Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE). <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 25-37.	1.1	19
185	Emerging Therapeutics for Patients with Triple-Negative Breast Cancer. <i>Current Oncology Reports</i> , 2021, 23, 57.	1.8	30
186	A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience. <i>Oncologist</i> , 2021, 26, e769-e779.	1.9	48
187	Canakinumab with and without pembrolizumab in patients with resectable non-small-cell lung cancer: CANOPY-N study design. <i>Future Oncology</i> , 2021, 17, 1459-1472.	1.1	25
188	Immune Checkpoint Inhibitors in Prostate Cancer. <i>Cancers</i> , 2021, 13, 2187.	1.7	48
189	Genomic correlates of response and resistance to immune checkpoint inhibitors in carcinomas of unknown primary. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13583.	1.7	15
191	Cancer of Unknown Primary in the Molecular Era. <i>Trends in Cancer</i> , 2021, 7, 465-477.	3.8	35
192	Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma. <i>Drugs and Aging</i> , 2021, 38, 579-591.	1.3	5
193	Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?. <i>Cancer Treatment Reviews</i> , 2021, 97, 102204.	3.4	24
194	Oncological evaluation in the perioperative period using cfDNA with BRAF V600E mutation in patients with colorectal cancer. <i>Scientific Reports</i> , 2021, 11, 13263.	1.6	1
195	Nivolumab: 5 Years Since FDA Approval of the First Checkpoint Inhibitor for Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2021, 5, 63-71.	0.2	2
196	Management of Bladder Cancer: The First Inning of a New Era of Rapid Advances. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, xiii-xx.	0.9	0
197	New Therapeutic Strategies in Advanced Nonoperable or Metastatic HER2-positive Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021, 81, 666-678.	0.8	1
198	The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials. <i>ESMO Open</i> , 2021, 6, 100124.	2.0	75

#	ARTICLE	IF	CITATIONS
199	Investigative Landscape in Advanced Non-Melanoma Skin Cancers. Current Treatment Options in Oncology, 2021, 22, 56.	1.3	2
200	Postoperative radiotherapy after upfront radical prostatectomy: debated issues at a turning point—a survey exploring management trends on behalf of AIRO (Italian Association of Radiotherapy and Oncology). <i>Journal of Radiotherapy in Oncology</i> , 2021, 124, 107-114.	0.784314	0
201	The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. <i>Cancer Communications</i> , 2021, 41, 747-795.	3.7	323
202	Personalizing Localized Prostate Cancer: Validation of a Combined Clinical Cell-cycle Risk (CCR) Score Threshold for Prognosticating Benefit From Multimodality Therapy. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 296-304.e3.	0.9	6
203	Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1369-1378.	0.5	31
204	Exploratory analysis of clinical benefit of ipilimumab and nivolumab treatment in patients with metastatic melanoma from a single institution. <i>Clinical and Translational Oncology</i> , 2022, 24, 319-330.	1.2	3
205	A Systematic Review and Meta-analysis of Dual Therapy in Patients With Advanced Renal Cell Carcinoma of Favourable Risk. <i>Urology</i> , 2021, 157, 8-14.	0.5	3
206	Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2109-2120.	0.5	75
207	Response to “The need for validation of MI GPSai in patients with CUP: Comment on: “Machine learning analysis using 77,044 genomic and transcriptomic profiles to accurately predict tumor type” by J Abraham et al.”. <i>Translational Oncology</i> , 2021, 14, 101093.	1.7	0
208	Novel and Promising Systemic Treatment Approaches in Mesothelioma. <i>Current Treatment Options in Oncology</i> , 2021, 22, 89.	1.3	2
209	Loss of cancer cell STAT1 improves response to radiation therapy and promotes T cell activation in head and neck squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2021, , 1.	2.0	4
211	Site-specific chemotherapy based on gene expression profiling versus empirical chemotherapy for people with cancer of unknown primary site. <i>The Cochrane Library</i> , 2021, 2021, .	1.5	0
213	A review of immune checkpoint blockade in breast cancer. <i>Seminars in Oncology</i> , 2021, 48, 208-225.	0.8	11
214	Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1718-1732.	0.5	141
215	Systemic Therapy Improvements Will Render Locoregional Treatments Obsolete for Patients with Cancer with Liver Metastases. <i>Surgical Oncology Clinics of North America</i> , 2021, 30, 189-204.	0.6	0
217	Triplet combination of BRAF, MEK and PD-1/PD-L1 blockade in melanoma: the more the better?. <i>Current Opinion in Oncology</i> , 2021, 33, 133-138.	1.1	14
218	Immunotherapy as a Precision Medicine Tool for the Treatment of Prostate Cancer. <i>Cancers</i> , 2021, 13, 173.	1.7	14
219	Immune Checkpoint Inhibitors in the Treatment of HCC. <i>Frontiers in Oncology</i> , 2020, 10, 601240.	1.3	77

#	ARTICLE	IF	CITATIONS
220	Análisis de supervivencia de los pacientes con cáncer de próstata con factores patológicos desfavorables tratados con prostatectomía radical y radioterapia de rescate tras la recidiva y persistencia bioquímica. <i>Actas Urológicas Españolas</i> , 2020, 44, 701-707.	0.3	3
221	Pathologic response at the epicenter of the treatment decision-making process in Human Epidermal Receptor-2 Type 2 overexpressing (Her2+) Early Breast Cancer (EBC): Challenges and opportunities for financially-constrained healthcare systems. <i>Breast</i> , 2020, 54, 331-334.	0.9	2
222	Italian Clinical Practice Guidelines on Cholangiocarcinoma – Part II: Treatment. <i>Digestive and Liver Disease</i> , 2020, 52, 1430-1442.	0.4	35
223	Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2020, 78, 834-844.	0.9	47
224	Retrospective Evaluation of the Use of Pembrolizumab in Malignant Mesothelioma in a Real-World Australian Population. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100075.	0.6	8
225	Checkpoint inhibitor immunotherapy in kidney cancer. <i>Nature Reviews Urology</i> , 2020, 17, 137-150.	1.9	162
226	Molecular Biological Features of Nottingham Histological Grade 3 Breast Cancers. <i>Annals of Surgical Oncology</i> , 2020, 27, 4475-4485.	0.7	34
227	Insights from the genetic and transcriptional characterization of a cancer of unknown primary (CUP) Tumor. <i>Journal of Clinical Oncology</i> , 2020, 38, 3314-3324.	3.3	4
228	Clinical and Translational Research Challenges in Biliary Tract Cancers. <i>Current Medicinal Chemistry</i> , 2020, 27, 4756-4777.	1.2	21
229	Treatment sequence of first and second generation tyrosine kinase inhibitor followed by osimertinib in EGFR-mutated non-small-cell lung cancer: a real life study. <i>Future Oncology</i> , 2020, 16, 1115-1124.	1.1	4
230	An Introduction to the Current Management of Ovarian Cancer in the Era of Precision Oncology. <i>Journal of Clinical Oncology</i> , 2021, 39, 19-57.		0
231	Ramucirumab plus paclitaxel for gastric cancer in China. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 975-976.	3.7	2
232	Cancer of Unknown Primary: Diagnosis and Treatment. <i>Korean Journal of Medicine</i> , 2021, 96, 408-414.	0.1	0
233	Immunotherapy in Advanced Gastroesophageal Tumors: The Best of the Current Knowledge. <i>Healthbook TIMES Oncology Hematology</i> , 2019, 18-21.	0.1	0
235	Systemic therapy of hepatocellular carcinoma: reality and prospects. <i>Annals of HPB Surgery</i> , 2020, 25, 27-38.	0.1	2
236	Immune checkpoint inhibition for the treatment of cancers: An update and critical review of ongoing clinical trials. <i>Clinical Immunology</i> , 2021, 232, 108873.	1.4	19
237	Genetic Landscape and Emerging Therapies in Uveal Melanoma. <i>Cancers</i> , 2021, 13, 5503.	1.7	17
238	Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown Primary. <i>JCO Precision Oncology</i> , 2021, 5, 1687-1698.	1.5	6

#	ARTICLE	IF	CITATIONS
239	Clinical case of long-term use of atezolizumab and bevacizumab in the first-line treatment of recurrence of non-small cell lung cancer. Meditsinskiy Sovet, 2020, , 242-247.	0.1	0
240	Uropathology macroscopy: a pragmatic approach. Diagnostic Histopathology, 2020, 26, 312-319.	0.2	1
241	CUP-Syndrom. , 2022, , 475-480.		0
242	Malignant neoplasm of the bronchi and lung: Russian clinical guidelines. Journal of Modern Oncology, 2021, 23, 369-402.	0.1	5
243	Real-world data analysis of patients with cancer of unknown primary. Scientific Reports, 2021, 11, 23074.	1.6	13
245	Evaluation of Targeted Next-Generation Sequencing for the Management of Patients Diagnosed with a Cancer of Unknown Primary. Oncologist, 2022, 27, e9-e17.	1.9	8
247	Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. The Cochrane Library, 2022, 2022, CD007929.	1.5	22
248	Evolving role of immunotherapy in small cell lung cancer. Seminars in Cancer Biology, 2022, 86, 868-874.	4.3	19
249	SEOM–GECOD clinical guideline for unknown primary cancer (2021). Clinical and Translational Oncology, 2022, 24, 681-692.	1.2	7
251	Site-specific therapy in cancers of unknown primary site: a systematic review and meta-analysis. ESMO Open, 2022, 7, 100407.	2.0	10
252	SEOM-GETTHI clinical guideline for the practical management of molecular platforms (2021). Clinical and Translational Oncology, 2022, 24, 693-702.	1.2	1
253	Emerging immunotherapy for HCC: A guide for hepatologists. Hepatology, 2022, 75, 1604-1626.	3.6	97
254	Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer. Breast, 2022, 62, S70-S79.	0.9	10
255	The Economic Burden of Recurrence in Triple-Negative Breast Cancer Among Working Age Patients in the United States. Advances in Therapy, 2022, 39, 943-958.	1.3	4
256	Immunotherapy in triple-negative breast cancer: A literature review and new advances. World Journal of Clinical Oncology, 2022, 13, 219-236.	0.9	16
258	Therapeutic options for the management of hepatocellular carcinoma. , 2022, , 43-62.		0
259	Intrahepatic cholangiocarcinoma hidden within cancer of unknown primary. British Journal of Cancer, 2022, 127, 531-540.	2.9	11
260	Identification of tissue of origin in cancer of unknown primary using a targeted bisulfite sequencing panel. Epigenomics, 2022, , .	1.0	1

#	ARTICLE	IF	CITATIONS
261	Neoadjuvant Chemotherapy for Nonmetastatic Breast Cancer. <i>Advances in Oncology</i> , 2022, 2, 47-61.	0.1	2
262	Systematic review of the CUP trials characteristics and perspectives for next-generation studies. <i>Cancer Treatment Reviews</i> , 2022, 107, 102407.	3.4	13
263	Neurotropic Cutaneous Malignancies: Case Report on Keratinocyte Derived Malignancies of the Head and Neck With Perineural Invasion. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	0
264	Hypoxia-driven metabolic heterogeneity and immune evasive behaviour of gastrointestinal cancers: Elements of a recipe for disaster. <i>Cytokine</i> , 2022, 156, 155917.	1.4	1
266	Real-world treatment patterns of metastatic non-small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors. <i>Cancer Medicine</i> , 2023, 12, 159-169.	1.3	8
268	Emerging insights on immunotherapy in liver cancer. <i>Antioxidants and Redox Signaling</i> , 0, , .	2.5	4
269	New Genetic Technologies in Diagnosis and Treatment of Cancer of Unknown Primary. <i>Cancers</i> , 2022, 14, 3429.	1.7	5
270	Multi-omic analysis in carcinoma of unknown primary (<sc>CUP</sc>): therapeutic impact of knowing the unknown. <i>Molecular Oncology</i> , 0, , .	2.1	6
271	CLINICAL AND ECONOMIC EVALUATION OF ATEZOLIZUMAB + VEMURAFENIB + COBIMETINIB COMBINATION AND NIVOLUMAB + IPILIMUMAB COMBINATION: ADMINISTRATION IN METASTATIC MELANOMA TREATMENT WITH BRAF-CONFIRMED MUTATION IN ADULT PATIENTS. <i>Farmatsiya I Farmakologiya</i> , 2022, 10, 278-288.	0.2	1
272	Histopathological Evaluation and Molecular Diagnostic Tests for Peritoneal Metastases with Unknown Primary Site—a Review. <i>Indian Journal of Surgical Oncology</i> , 0, , .	0.3	0
273	Advancements in Low-Grade Serous Carcinoma of the Ovary and Peritoneum. <i>Current Oncology Reports</i> , 2022, 24, 1549-1555.	1.8	5
275	Intermittent MEK inhibition for the treatment of metastatic uveal melanoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
276	Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
277	Integrated analysis of cervical squamous cell carcinoma cohorts from three continents reveals conserved subtypes of prognostic significance. <i>Nature Communications</i> , 2022, 13, .	5.8	13
280	Polyphenols: a route from bioavailability to bioactivity addressing potential health benefits to tackle human chronic diseases. <i>Archives of Toxicology</i> , 2023, 97, 3-38.	1.9	16
281	A comparison of <sc>DNA</sc> sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary. <i>Journal of Pathology</i> , 2023, 259, 81-92.	2.1	8
282	Role of immunotherapy in downsizing hepatocellular carcinoma prior to liver transplantation. <i>World Journal of Transplantation</i> , 0, 12, 331-346.	0.6	2
283	The effect of organ-specific tumor microenvironments on response patterns to immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0

#	ARTICLE	IF	CITATIONS
284	Molecular analysis for refractory rare cancers: Sequencing battle continues – learnings for the MOSCATO-01 study. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 181, 103888.	2.0	4
285	Comparison of the efficacy and safety in the treatment strategies between chemotherapy combined with antiangiogenic and with immune checkpoint inhibitors in advanced non-small cell lung cancer patients with negative PD-L1 expression: A network meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
286	Malignant neoplasm of the bronchi and lung: Russian clinical guidelines. <i>Journal of Modern Oncology</i> , 2022, 24, 269-304.	0.1	2
287	Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics. <i>ESMO Open</i> , 2022, 7, 100611.	2.0	5
288	The evolving strategies for the management of patients with metastatic gastric cancer: A narrative review and expert opinion. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	1
289	Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2023, 34, 228-246.	0.6	38
290	Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
291	Lung Immunotherapy in the Elderly with NSCLC – the Who, the What, and the When. , 2023, , .		0
292	Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary. , 2023, 11, e005809.		4
294	Clinical outcomes of patients diagnosed with cancer of unknown primary or malignancy of undefined primary origin who were referred to a regional cancer center. <i>International Journal of Clinical Oncology</i> , 2023, 28, 644-653.	1.0	1
295	Significance of Distinct Liquid Biopsy Compartments in Evaluating Somatic Mutations for Targeted Therapy Selection in Cancer of Unknown Primary. <i>Journal of Gastrointestinal Cancer</i> , 2023, 54, 1276-1285.	0.6	0
298	Cancer of unknown primary (CUP) through the lens of precision oncology: a single institution perspective. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 8225-8234.	1.2	0
308	The practical utility of AI-assisted molecular profiling in the diagnosis and management of cancer of unknown primary: an updated review. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 0, , .	1.4	2
311	Cancer of unknown primary – state of the art. <i>Memo - Magazine of European Medical Oncology</i> , 2024, 17, 30-34.	0.3	1
318	Malignome unbekannter PrimÄrlokalisierung. , 2024, , 1053-1069.		0